{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.221","value":"-5.83"},{"comment":"Standard deviation could not be calculated for a single participant","groupId":"OG001","spread":"NA","value":"9.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Emotional score, Week 3, n=6,1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.735","value":"-19.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Emotional score, Week 7, n=5,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.497","value":"-44.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Emotional score, Week 10, n=3,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.897","value":"-10.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Emotional score, Week 16, n=3,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.768","value":"-18.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Emotional score, Week 24, n=2,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.742","value":"-1.42"},{"comment":"Standard deviation could not be calculated for a single participant","groupId":"OG001","spread":"NA","value":"30.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Functioning score, Week 3, n=6,1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.000","value":"-13.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Functioning score, Week 7, n=5,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.820","value":"-35.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Functioning score, Week 10, n=3,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.788","value":"-13.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Functioning score, Week 16, n=3,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.919","value":"-18.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Functioning score, Week 24, n=2,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.055","value":"6.55"},{"comment":"Standard deviation could not be calculated for a single participant","groupId":"OG001","spread":"NA","value":"12.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Symptoms score, Week 3, n=6,1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.489","value":"-2.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Symptoms score, Week 7, n=5,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.927","value":"-29.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Symptoms score, Week 10, n=3,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.670","value":"-8.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Symptoms score, Week 16, n=3,0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.102","value":"-14.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Symptoms score, Week 24, n=2,0"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"The effects of treatment on disease-related symptoms/quality of life was assessed using the Skindex-29 Questionnaire, which inquires about how often (Never, Rarely, Sometimes, Often, All the time) during the previous 4 weeks the participant experienced the effect described in each of 29 items divided into 3 domains: Emotional (10 items), Symptoms (7 items) and Functioning (12 items). Responses to each item are transformed to a linear scale of 100, varying from 0 (no effect) to 100 (effect experienced all the time). Skindex-29 scores were reported as three individual domain scale scores; a scale score is the mean of a participant's responses to items in a given domain. Each domain score ranges from 0 (no effect) to 100 (effect experienced all the time), higher score implies higher impact of skin disease. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is defined is post-dose visit value minus Baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"MEAN","populationDescription":"All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).","reportingStatus":"POSTED","timeFrame":"Baseline (pre-dose Week1 Day1) and Week 3, Week 7, Week 10, Week 16 and Week 24","title":"Part 2: Change From Baseline in Skindex-29 Domain Scores (Emotional, Functioning and Symptoms Score) for CTCL Cohort","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}